Nasdaq Stock Market : declared in Merck's cholesterol drug clears main goal in late-stage study

CLOSE X Edit Favorites Enter up to 25 symbols separated by commas or spaces in the text box below. This will now be your default target page; unless you change your configuration again, or you delete your cookies. Are you sure you want to change your settings? These symbols will be available during your session for use on applicable pages. If, at any time, you are interested in reverting to our default settings, please select Default Setting above.If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com CLOSE X Please confirm your selection: You have selected to change your default setting for the Quote Search.


Merck shares fall despite saying cholesterol drug met primary goal in study

Merck said Tuesday its cholesterol drug Anacetrapib met its primary goal in a study, significantly reducing coronary heart disease. BMO Capital Markets' Alex Arfaei also said the release's wording suggests the study results "may not be very clinically meaningful" and "may not justify the safety issues." Results of the study on 30,000 individuals will be presented on Aug. 29 at a European Society of Cardiology meeting. However, Arfaei noted that expectations for the drug are "very low" and maintained his outperform rating on the stock. The study's positive result generally surprised stock analysts, but they had mixed forecasts on how much it would help Merck facebook/" target="_blank">shares.

Merck's cholesterol drug clears main goal in late-stage study
The study was testing Merck's drug, anacetrapib, in patients who were already receiving an effective LDL cholesterol lowering regimen. CETP inhibitors block a protein that transfers HDL cholesterol to LDL cholesterol, resulting in higher levels of HDL and lower LDL levels. Merck & Co Inc said on Tuesday its experimental cholesterol drug met the main goal of reducing coronary heart diseases in a late-stage study, sending its facebook/" target="_blank">shares up 2.4 percent in premarket trading. Over the past decade, three experimental CETP inhibitors from Pfizer, Roche and Eli Lilly have failed in tests. Anacetrapib belongs to a class of drugs called cholesteryl ester transfer protein (CETP) inhibitor.


collected by :Lucy William

To follow all the new news about From Addiction to Recovery

Comments

Popular posts from this blog

Cannabis addiction and its side effects

DMT Facts and side effects

Fresh drug abuse curing Center can Be Coming To Westchester